Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.

ABSTRACT:

Background/aims

Real-life anti-vascular endothelial growth factor (VEGF) therapy use in patients with wet age-related macular degeneration (wAMD) was assessed in a retrospective, observational study in Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela.

Methods

Medical records of patients with wAMD, who started ranibizumab treatment between 1 January 2009 and 31 August 2009, were evaluated. Data were collected until the end of treatment and/or monitoring or until 31 August 2011.

Results

2227 patients who received ≥1 anti-VEGF injection with a baseline visual acuity assessment and ≥1 postbaseline visual acuity assessment for the treated eye were evaluated. Visual acuity improved until about day 120; thereafter, visual acuity gains were not maint

SUBMITTER: Holz FG 

PROVIDER: S-EPMC4316940 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature